EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

T-Cell Immunoglobulin and Mucin Domain 3 (TIM-3) Gene Expression as a Negative Biomarker of B-Cell Acute Lymphoblastic Leukemia

Fatemah S Basingab iD, Manar Bashanfer, Aisha A Alrofaidi iD, Ahmed S Barefah iD, Rawan Hammad iD, Hadil M Alahdal, Jehan S Alrahimi iD, Kawther A Zaher iD, Sabah Hassan iD, Ali H Algiraigri iD, Mai M El-Daly iD, Saleh A Alkarim iD und 1 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252011148 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Fatemah S Basingab und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Hepatitis A Virus Cellular Receptor 2. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Deputyship for Research and Innovation, Ministry of Education, Saudi Arabia, Deputyship for Research and Innovation, Ministry of Education, Saudi Arabia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

B-cell acute lymphoblastic leukemia (B-ALL) accounts for 85% of all childhood ALL. Malignancies exhaust T and B cells, resulting in an increased expression of immune checkpoint receptors (ICRs), such as T-cell immunoglobulin and mucin domain 3 (TIM-3). TIM-3 has been found to be dysregulated in different types of cancer. However, there is a lack of rigorous studies on the TIM-3 expression in B-ALL. The current study aimed to measure the expression of TIM-3 at the gene and protein levels and evaluate the potential of TIM-3 as a biomarker in B-ALL. A total of 28 subjects were recruited between 2021 and 2023, comprising 18 subjects diagnosed with B-ALL and 10 non-malignant healthy controls. The B-ALL patients were divided into three groups: newly diagnosed (four patients), in remission (nine patients), and relapse/refractory (five patients). The expression levels of TIM-3 were evaluated using the real-time qPCR and ELISA techniques. The results revealed that the TIM-3 expression was significantly downregulated in the malignant B-ALL patients compared to the non-malignant healthy controls in the mRNA (FC = −1.058 ± 0.3548, p = 0.0061) and protein blood serum (p = 0.0498) levels. A significant TIM-3 gene reduction was observed in the relapse/refractory cases (FC = −1.355 ± 0.4686, p = 0.0327). TIM-3 gene expression allowed for significant differentiation between patients with malignant B-ALL and non-malignant healthy controls, with an area under the curve (AUC) of 0.706. The current study addressed the potential of reduced levels of TIM-3 as a negative biomarker for B-ALL patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorHepatitis A Virus Cellular Receptor 2AdolescentChildChild, PreschoolFemaleHumansMaleCase-Control StudiesGene Expression Regulation, LeukemicPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Stichwörter der Autor:innen

B-cell acute lymphoblastic leukemiaCD4+ T cellsT-cell immunoglobulin and mucin domain 3acute lymphoblastic leukemiaimmune checkpoint receptor (ICR)programmed cell death-1tumor microenvironment

Substanzen

Biomarkers, TumorHAVCR2 protein, humanHepatitis A Virus Cellular Receptor 2

Autor:innen und Institutionen

  • Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  • Immunology Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  • Hematology Department, Faculty of Medicine, King Abdulaziz University Hospital, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  • Hematology Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  • Department of Biology, Faculty of Science, Princes Nourah bint Abdulrahman University, Riyadh 12211, Saudi Arabia.
  • Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia.

ORCID-Profile: Fatemah S Basingab, Aisha A Alrofaidi, Ahmed S Barefah, Rawan Hammad, Jehan S Alrahimi, Kawther A Zaher, Sabah Hassan, Ali H Algiraigri, Mai M El-Daly, Saleh A Alkarim, Alia M Aldahlawi

Förderung

  • the Deputyship for Research and Innovation, Ministry of Education, Saudi Arabia
  • Deputyship for Research and Innovation, Ministry of Education, Saudi Arabia

Zitieren

APA

Basingab, F. S., Bashanfer, M., Alrofaidi, A. A., Barefah, A. S., Hammad, R., Alahdal, H. M., Alrahimi, J. S., Zaher, K. A., Hassan, S., Algiraigri, A. H., El-Daly, M. M., Alkarim, S. A., & Aldahlawi, A. M. (2024). T-Cell Immunoglobulin and Mucin Domain 3 (TIM-3) Gene Expression as a Negative Biomarker of B-Cell Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252011148

Vancouver

Basingab FS, Bashanfer M, Alrofaidi AA, Barefah AS, Hammad R, Alahdal HM, et al. T-Cell Immunoglobulin and Mucin Domain 3 (TIM-3) Gene Expression as a Negative Biomarker of B-Cell Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252011148

BibTeX
@article{Basingab2024,
  author = {Basingab, Fatemah S and Bashanfer, Manar and Alrofaidi, Aisha A and Barefah, Ahmed S and Hammad, Rawan and Alahdal, Hadil M and Alrahimi, Jehan S and Zaher, Kawther A and Hassan, Sabah and Algiraigri, Ali H and El-Daly, Mai M and Alkarim, Saleh A and Aldahlawi, Alia M},
  title = {T-Cell Immunoglobulin and Mucin Domain 3 (TIM-3) Gene Expression as a Negative Biomarker of B-Cell Acute Lymphoblastic Leukemia},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252011148}
}
Kostenlos starten →